• Publications
  • Influence
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
TLDR
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
TLDR
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
TLDR
Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
TLDR
Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
TLDR
First-line treatment with cetuximab plus FOLFIRI, as compared with F OLFIRI alone, reduced the risk of progression of metastatic colorectal cancer and was limited to patients with KRAS wild-type tumors.
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
TLDR
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated.
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
TLDR
Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
TLDR
These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
...
...